#ASCO25 Abst 5045: Update PCa risk groups by PSMA-PET PROMISE Anders Bjartell Michael Hofman ▶️2012: introduction of PSMA-PET ▶️2018: definition of PROMISE criteria (V1 and V2) ▶️PPP2 monograms of PSMA-PET yield superior accuracy compared to NCCN or EAU risk groups OncoAlert Bárbara Melão, MD, PhD

#ASCO25 #ProstateCancer Abst 5048: Long-term safety of Ra-223 in mCRPC tombal 👉REASSURE 7-year FU ✨Median of 6 doses ❗️50% pts had any adverse events / 11% G>2 / 5% discontinuation / 10% fractures 👉favorable safety profile ✨Median OS 15.6m OncoAlert Regina Barragan-Carrillo

Industry news‼️ #ProstateCancer Interim analysis of PSMAddition trial met its primary endpoint showing statistically significant benefit in mHSPC with the addition of Lu-PSMA ⁦OncoAlert⁩ ⁦ novartis.com/news/media-rel…

#ASCO25 BULSSEYE Ph2 trial👉 Lu-PSMA in oligo mHSPC ▶️58 pts oHSPC, PSA DT<6, max of 5 Mets 👉 R 1:1 Lu-PSMA vs. deferred ADT ▶️1 Endpoint: PFS (without ADT) ✨Rationale: Lu-PSMA as MDT monotherapy in oligorecurrent HSPC to prolong ADT-free interval👉HR 0.07 (0.02-0.19, p<0.001)

#ASCO25 VIOLET Ph1/2 Michael Hofman First-in-human results of Tb-PSMA-I&T radioligand mCRPC ✔️Terbium: beta-emitter, higher energy, ultra-short path-length👉Auger electrons 👉better for micrometastases ✔️30 mCRPC pts after ARPI & CT; PSMA+ (SUVmax>20)👉no dose limiting toxicities

El Dr FLoscoMD desde #ASCO25 nos cuenta un resumen de dos estudios presentados: * Inmunoterapia puede combinarse con 177Lu-PSMA? #EVOLUTIONtrial by ANZUP * existe riesgo de hematopoyesis clonal con 177Lu-PSMA? Sub-análisis TheraP by ProsTIC UroToday.com 👇👇👇

Más tripletes en Cancer de Prostata metastasico sensible a Hornonas. Tripletes con Lutecio, Tripletes con Inhibidores PARP, tripletes con Capivasertib. Se va a ampliar el menú de opciones. Si solo usamos hornonas nos quedaremos atrás. Pedro C Barata, MD MSc FACP onconnecta2025

New data from Denmark suggest improved survival with salvage radiotherapy in the PSMA PET/CT era. jnm.snmjournals.org/content/early/… SNMMI 📊The retrospective analysis excludes patients ineligible for RT based on PSMA PET/CT 💡Randomized data is ideal but challenging in 2025 with

🚨 NEW #PlatinumOpinion in European Urology by M. J. Roberts, Giorgio Gandaglia et al : 💡 Is extended pelvic lymph node dissection (ePLND) still justified in prostate cancer? 📉 No oncologic benefit in RCTs ⚠️ Up to 20% complication rate 🧬 PSMA PET reshapes staging 🔄 2024 EAU

#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in The Lancet Oncology : thelancet.com/journals/lanon… 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣Very few

🔬 La cirugía radioguiada con PSMA está transformando la detección de ganglios metastásicos en cáncer de próstata. En Latinoamérica, el camino ha iniciado. 🌎 💻Webinar - GRATUITO 🧵👇👇

Distintos expertos internacionales contarán su experiencia en esta innovadora técnica quirúrgica y su aporte en el mundo real

⚡️ FDA analysis in metastatic RCC: Cytoreductive nephrectomy before ICI + VEGFi was associated with: ✔️ Longer OS (46 vs. 28 months) ✔️ Improved PFS and ORR academic.oup.com/jnci/article/1… #KidneyCancer #Immunotherapy

68yo patient, PSA 7040 mg/ml, Performance Status 1, ISUP 4, de novo presentation (real world in Latam…) Michael Hofman UroTeragLATAM Advanced Prostate Cancer Consensus Conference Jeremie Calais FLoscoMD Daniel Castellano Hector Manuel Sanchez Lopez DR CARVAJAL Martín Angel Rodrigo Sanchez Roger Dra. María Natalia Gandur Quiroga

Are the overall response and individual lesion responses of patients with #mCRPC dependent on the absorbed dose of ¹⁷⁷Lu-PSMA-617 radiopharmaceutical therapy? ow.ly/xWrQ50WGwzo #RPTherapy #NuclearMedicine @LisaBodei @Simoneskrebs